276 related articles for article (PubMed ID: 22379188)
1. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
[TBL] [Abstract][Full Text] [Related]
2. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
4. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
7. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
Chen C; Huang R; MacLean A; Muzikansky A; Mukundan S; Wen PY; Norden AD
J Neurooncol; 2013 Nov; 115(2):267-76. PubMed ID: 23974656
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.
Colavolpe C; Metellus P; Mancini J; Barrie M; Béquet-Boucard C; Figarella-Branger D; Mundler O; Chinot O; Guedj E
J Neurooncol; 2012 May; 107(3):527-35. PubMed ID: 22169956
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M
J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
[TBL] [Abstract][Full Text] [Related]
12. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
[TBL] [Abstract][Full Text] [Related]
13. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.
Wardak M; Schiepers C; Dahlbom M; Cloughesy T; Chen W; Satyamurthy N; Czernin J; Phelps ME; Huang SC
Clin Cancer Res; 2011 Oct; 17(20):6553-62. PubMed ID: 21868765
[TBL] [Abstract][Full Text] [Related]
14. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
15. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
16. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
[TBL] [Abstract][Full Text] [Related]
17. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
[TBL] [Abstract][Full Text] [Related]
20. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
